Zamicastat

Zamicastat

Clinical data
Other names	BIA-5-1058; BIA 5-1058
Drug class	Dopamine β-hydroxylase inhibitor
Identifiers
IUPAC name 4-[2-(benzylamino)ethyl]-3-[(3R)-6,8-difluoro-3,4-dihydro-2H-chromen-3-yl]-1H-imidazole-2-thione
CAS Number	1080028-80-3
PubChem CID	25052630
DrugBank	DB12389
ChemSpider	32701723
UNII	YLU32D0DNV
ChEMBL	ChEMBL4594440
CompTox Dashboard (EPA)	DTXSID80148358
Chemical and physical data
Formula	C21H21F2N3OS
Molar mass	401.48 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1[C@H](COC2=C1C=C(C=C2F)F)N3C(=CNC3=S)CCNCC4=CC=CC=C4
InChI InChI=1S/C21H21F2N3OS/c22-16-8-15-9-18(13-27-20(15)19(23)10-16)26-17(12-25-21(26)28)6-7-24-11-14-4-2-1-3-5-14/h1-5,8,10,12,18,24H,6-7,9,11,13H2,(H,25,28)/t18-/m1/s1 Key:ZSSLCFLHEFXANG-GOSISDBHSA-N

Zamicastat (INNTooltip International Nonproprietary Name; developmental code name BIA-5-1058) is a peripherally selective dopamine β-hydroxylase (DBH) inhibitor which is under development for the treatment of pulmonary arterial hypertension (PAH) and heart failure. It is structurally related to etamicastat and is said to be an improved version of this drug. As of July 2022, zamicastat is in phase 2 clinical trials for PAH and phase 1 clinical trials for heart failure. However, no recent development has been reported for heart failure.

See also

• Nepicastat